Table 2.
Meta-analysis | Sensitivity analysesa | |||||
---|---|---|---|---|---|---|
Outcome measures | RR | 95 % CI | P | RR | 95 % CI | P |
TCZCOMBI vs. TCZMONO | ||||||
DAS28 < 2.6 | 1.21 | 1.09, 1.36 | <0.001 | 1.20 | 1.07, 1.34 | 0.002 |
ACR20 | 1.05 | 0.99, 1.12 | 0.11 | 1.05 | 0.98, 1.11 | 0.17 |
ACR50 | 1.14 | 1.03, 1.26 | 0.008 | 1.13 | 1.02, 1.25 | 0.02 |
ACR70 | 1.19 | 0.94, 1.51 | 0.14 | 1.12 | 0.95, 1.33 | 0.19 |
AEs | 1.08 | 0.97, 1.21 | 0.17 | 1.09 | 0.86, 1.38 | 0.48 |
SAEs | 1.40 | 1.03, 1.92 | 0.03 | 1.34 | 0.79, 2.27 | 0.27 |
TCZCOMBI vs. csDMARD | ||||||
DAS28 < 2.6 | 8.77 | 4.10, 18.75 | <0.001 | 10.39 | 4.38, 24.65 | <0.001 |
ACR20 | 2.10 | 1.48, 2.99 | <0.001 | 2.15 | 1.45, 3.19 | <0.001 |
ACR50 | 3.00 | 1.80, 4.99 | <0.001 | 3.24 | 1.82, 5.78 | <0.001 |
ACR70 | 5.32 | 2.31, 12.25 | <0.001 | 6.23 | 2.29, 16.93 | <0.001 |
AEs | 1.12 | 1.06, 1.18 | <0.001 | 1.14 | 1.07, 1.20 | <0.001 |
SAEs | 1.21 | 0.91, 1.60 | 0.19 | 1.13 | 0.80, 1.60 | 0.48 |
TCZMONO vs. csDMARD | ||||||
DAS28 < 2.6 | 3.95 | 2.23, 7.00 | <0.001 | 4.50 | 2.34, 8.64 | <0.001 |
ACR20 | 1.68 | 1.21, 2.32 | 0.002 | 1.71 | 1.18, 2.48 | 0.005 |
ACR50 | 1.87 | 1.19, 2.95 | 0.007 | 2.01 | 1.18, 3.42 | 0.01 |
ACR70 | 2.11 | 1.18, 3.78 | 0.01 | 2.49 | 1.29, 4.81 | 0.007 |
AEs | 1.08 | 1.01, 1.15 | 0.03 | 1.13 | 0.92, 1.39 | 0.24 |
SAEs | 1.21 | 0.87, 1.69 | 0.26 | 1.37 | 0.64, 2.93 | 0.42 |
aThe CHARISMA study was excluded from all meta-analyses; the FUNCTION study was excluded from all meta-analyses of safety outcomes (adverse events (AEs) and serious AEs (SAEs)); the SAMURAI study was excluded from meta-analyses of the safety of tocilizumab monotherapy (TCZMONO) vs. a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD); the SURPRISE study was excluded (from meta-analyses of the safety of tocilizumab combination therapy (TCZCOMBI) vs. TCZMONO. RR relative risk, CI confidence interval, DAS28 Disease Activity Score in 28 joints, ACR American college of Rheumatology, AEs adverse events, SAEs serious AEs